NASDAQ:NMAD Lixte Biotechnology (NMAD) Stock Price, News & Analysis $3.75 +0.15 (+4.17%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Lixte Biotechnology Stock (NASDAQ:NMAD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lixte Biotechnology alerts:Sign Up Key Stats Today's Range$3.44▼$3.8350-Day Range$3.27▼$7.5152-Week Range$2.36▼$8.38Volume228,402 shsAverage Volume198,016 shsMarket Capitalization$60.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lixte Biotechnology Holdings, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target protein phosphatase 2A (PP2A), an enzyme involved in regulating cell growth, survival and response to treatment. The company’s research is based on the premise that inhibiting PP2A may help make cancer cells more vulnerable to existing therapies. Lixte’s lead investigational compound is LB-100, a small-molecule PP2A inhibitor being evaluated in combination with other cancer treatments. The company has explored LB-100 in preclinical studies and early-stage clinical trials involving solid tumors and other malignancies. Lixte’s development strategy centers on combining its PP2A-targeting compounds with chemotherapy, radiation, immunotherapy or other targeted treatments. Founded in 2001, Lixte is headquartered in Pasadena, California. As a clinical-stage company, it focuses primarily on research and development and does not have an established commercial product portfolio. Its programs are directed toward potential applications in oncology, although the safety and effectiveness of its investigational treatments remain subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Lixte Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreNMAD MarketRank™: Lixte Biotechnology scored higher than 14% of companies evaluated by MarketBeat, and ranked 619th out of 667 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingLixte Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLixte Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Lixte Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lixte Biotechnology is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lixte Biotechnology is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLixte Biotechnology has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.50% of the float of Lixte Biotechnology has been sold short.Short Interest Ratio / Days to CoverLixte Biotechnology has a short interest ratio ("days to cover") of 3.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lixte Biotechnology has recently decreased by 6.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLixte Biotechnology does not currently pay a dividend.Dividend GrowthLixte Biotechnology does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.98 News SentimentLixte Biotechnology has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Industrials companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lixte Biotechnology this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Lixte Biotechnology to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders7.30% of the stock of Lixte Biotechnology is held by insiders.Percentage Held by Institutions5.10% of the stock of Lixte Biotechnology is held by institutions.Read more about Lixte Biotechnology's insider trading history. Receive NMAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMAD Stock News HeadlinesNOMAD Power Solutions Expands Its Canadian Commercial Presence with Appointment of Global Environmental Liquid Ltd. as Sales RepresentativeSeptember 25, 2026 | globenewswire.comNOMAD Power Solutions, Inc.: Nomad Power Solutions Files Expanded Business And Financial Disclosure Following Completion Of MergerSeptember 18, 2026 | finanznachrichten.deYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 29 at 1:00 AM | Profits Run (Ad)NOMAD POWER SOLUTIONS FILES EXPANDED BUSINESS AND FINANCIAL DISCLOSURE FOLLOWING COMPLETION OF MERGERSeptember 17, 2026 | globenewswire.comNomad Power Solutions Inc NMADSeptember 16, 2026 | morningstar.comMRented Fleets Are Winning the Infrastructure Buildout as Mega Projects MultiplySeptember 11, 2026 | prnewswire.comNOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERSSeptember 4, 2026 | globenewswire.comNOMAD Power Solutions, Inc. Receives DOE Authorization to Advance Vermont Long-Duration Energy Storage Project into Phase 3August 26, 2026 | globenewswire.comSee More Headlines NMAD Stock Analysis - Frequently Asked Questions How have NMAD shares performed this year? Lixte Biotechnology's stock was trading at $3.93 on January 1st, 2026. Since then, NMAD shares have decreased by 4.6% and is now trading at $3.75. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD) posted its quarterly earnings data on Friday, August, 14th. The company reported ($0.16) earnings per share for the quarter. When did Lixte Biotechnology's stock split? Lixte Biotechnology shares reverse split before market open on Monday, June 5th 2023.The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Lixte Biotechnology? Shares of NMAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lixte Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings8/14/2026Today9/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 4 weeks, NMAD's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Electrical Equipment Sub-IndustryElectrical Components & Equipment Current SymbolNASDAQ:NMAD Previous SymbolNASDAQ:LIXT CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees4Year Founded2006Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.49% Return on Assets-62.03% Debt Debt-to-Equity RatioN/A Current Ratio12.87 Quick Ratio12.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book3.57Miscellaneous Outstanding Shares16,100,000Free Float14,926,000Market Cap$60.38 million OptionableNot Optionable Beta1.30 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:NMAD) was last updated on 9/29/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
